Evidence map›Paper›PMID 8559666›Full record

ArticleNucleic acids research1995

Characterization of a silencer element in the first exon of the human osteocalcin gene.

Y P Li, W Chen, P Stashenko

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Y P LiDepartment of Cytokine Biology, Forsyth Dental Center, Boston, MA 02115, USA.
W Chen
P Stashenko
Novant Health Forsyth Medical Center · US

Funding

Role of Serotonin in Osteoclast DifferentationR01DE007378 · NIDCR · FORSYTH INSTITUTE · PI STASHENKO, PHILIP · 1985 to 2005
$1.7M
NUCLEAR PROTEINS AND OSTEOBLAST DIFFERENTIATIONR29DE010887 · NIDCR · FORSYTH INSTITUTE · PI LI, YI-PING · 1994 to 1998
–
NIDCR NIH HHS DE-07378NIDCR NIH HHS DE-10887
6 · The paper itself

Abstract

Osteocalcin, the major non-collagenous protein in bone, is transcribed in osteoblasts at the onset of extracellular matrix mineralization. In this study it was demonstrated that sequences located in the first exon of the human osteocalcin gene possess a differentiation-related osteocalcin silencer element (OSE). Osteocalcin was rendered transcribable in UMR-106 cells and proliferating normal osteoblasts after deletion of the -3 to +51 region. Site-specific mutagenesis of this region revealed that a 7 bp sequence (TGGCCCT) (+29 to +35) is critical for silencing function. Mobility shift assays demonstrated that a nuclear factor bound to the OSE. The OSE binding protein was present in proliferating normal pre-osteoblasts and in UMR-106 and ROS 17/2.8 osteosarcoma cells, but was absent from post-proliferative normal osteoblasts. The binding protein was inhibited by fragments containing the +29/+35 sequence, but not by other promoter fragments or by the consensus oligomers of unrelated nuclear factors AP-1 and Sp1. DNase 1 footprinting demonstrated that the OSE binding-protein protected the +17 to +36 portion of the first exon, consistent with the results of mapping studies and competitive mobility shift assays. It is hypothesized that this silencer is activated by complexing of the OSE binding protein to the OSE during the osteoblast proliferation stage and that the OSE binding protein is down-regulated at the onset of extracellular matrix mineralization.

Indexed as

AnimalsBase SequenceDNA FootprintingExonsHumansMolecular Sequence DataMutagenesis, Site-DirectedOsteocalcinRatsSequence AlignmentSequence AnalysisOsteocalcin

Identifiers

PMID8559666
PMCPMC307514
OpenAlexW2011402345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.